▲ +79.60% Upside Potential
This price target is based on 23 analysts offering 12 month price targets for Intercept Pharmaceuticals in the last 3 months. The average price target is $65.41, with a high forecast of $140.00 and a low forecast of $38.00. The average price target represents a 79.60% upside from the last price of $36.42.
The current consensus among 23 polled investment analysts is to hold stock in Intercept Pharmaceuticals. This rating has held steady since January 2019, when it changed from a Buy consensus rating.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.